» Articles » PMID: 9916890

HuR, a Novel Target of Anti-Hu Antibodies, is Expressed in Non-neural Tissues

Overview
Journal J Neuroimmunol
Specialty Neurology
Date 1999 Jan 23
PMID 9916890
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Paraneoplastic encephalomyelitis (PEM) is characterized by a diverse set of clinical signs that are limited to the nervous system. The serologic hallmark of PEM is the presence of circulating autoantibodies, collectively referred to as 'anti-Hu,' which immunoreact specifically with members of the Elav protein family. Until recently, the ELAV antigens were only detected in neurons, thus strongly supporting a role for anti-Hu antibodies in the selective neural tissue injury in PEM. The identification of HuR, however, a new member with a broad, non-neural pattern of RNA expression, raises several fundamental questions regarding PEM. First, why are non-neural tissues spared in PEM? Second, why is PEM predominantly associated with neuroendocrine tumors? To begin addressing these questions, we sought to determine whether the antibody response to HuR differs from the neural-specific counterparts in patients with PEM, and to characterize the protein expression pattern of this novel antigen in peripheral tissues and tumors. Using sera from 11 patients with Hu-positive PEM, we found that the majority of samples (73%) were weakly or non-reactive for recombinant HuR on Western blot, in contrast to consistently strong immunoreactivity with the neural-specific members HuD and Hel-N1. We also demonstrate that HuR is expressed at the protein level in both non-neural tissues and non-neuroendocrine tumors. These findings suggest that immunoreactive differences among Elav family members may contribute to the neural-restrictive pattern of tissue injury in patients with PEM.

Citing Articles

An Autoantigen Atlas From Human Lung HFL1 Cells Offers Clues to Neurological and Diverse Autoimmune Manifestations of COVID-19.

Wang J, Zhang W, Roehrl V, Roehrl M, Roehrl M Front Immunol. 2022; 13:831849.

PMID: 35401574 PMC: 8987778. DOI: 10.3389/fimmu.2022.831849.


The versatile role of HuR in Glioblastoma and its potential as a therapeutic target for a multi-pronged attack.

Guha A, Waris S, Nabors L, Filippova N, Gorospe M, Kwan T Adv Drug Deliv Rev. 2021; 181:114082.

PMID: 34923029 PMC: 8916685. DOI: 10.1016/j.addr.2021.114082.


A Master Autoantigen-ome Links Alternative Splicing, Female Predilection, and COVID-19 to Autoimmune Diseases.

Wang J, Roehrl M, Roehrl V, Roehrl M bioRxiv. 2021; .

PMID: 34373855 PMC: 8351778. DOI: 10.1101/2021.07.30.454526.


An Autoantigen-ome from HS-Sultan B-Lymphoblasts Offers a Molecular Map for Investigating Autoimmune Sequelae of COVID-19.

Wang J, Zhang W, Roehrl V, Roehrl M, Roehrl M bioRxiv. 2021; .

PMID: 33851168 PMC: 8043459. DOI: 10.1101/2021.04.05.438500.


A repertoire of 124 potential autoantigens for autoimmune kidney diseases identified by dermatan sulfate affinity enrichment of kidney tissue proteins.

Zhang W, Rho J, Roehrl M, Roehrl M, Wang J PLoS One. 2019; 14(6):e0219018.

PMID: 31237920 PMC: 6592568. DOI: 10.1371/journal.pone.0219018.